QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:GRPH

Graphite Bio (GRPH) Price Target & Analyst Ratings

$2.94
-0.02 (-0.68%)
(As of 06/7/2023 ET)
Compare
Today's Range
$2.90
▼
$3.02
50-Day Range
$2.41
▼
$3.38
52-Week Range
$1.59
▼
$4.48
Volume
64,399 shs
Average Volume
222,250 shs
Market Capitalization
$170.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.33
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Graphite Bio Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 9 Analyst Ratings

Consensus Analyst Price Target

$3.33
13.38% Upside
High Prediction$7.00
Average Prediction$3.33
Low Prediction$2.00
TypeCurrent
6/7/22 to 6/7/23		1 Month Ago
5/8/22 to 5/8/23		3 Months Ago
3/9/22 to 3/9/23		1 Year Ago
6/7/21 to 6/7/22
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
4 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$3.33$3.33$5.57$18.00
Predicted Upside13.38% Upside31.67% Upside102.48% Upside59.40% Upside
Get Graphite Bio Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GRPH and its competitors with MarketBeat's FREE daily newsletter.


GRPH Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GRPH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Graphite Bio Stock vs. The Competition

TypeGraphite BioMedical CompaniesS&P 500
Consensus Rating Score
1.89
2.66
2.49
Consensus RatingHoldBuyHold
Predicted Upside12.61% Upside1,247.99% Upside221.87% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/21/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetSector Perform$4.00 ➝ $3.00+22.95%
2/23/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeNeutral ➝ Underperform$3.00 ➝ $2.00-11.11%
2/23/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		O. Brayer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOverweight ➝ Neutral$8.00 ➝ $3.00+36.36%
2/23/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform
2/23/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform
2/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetEqual Weight$6.00 ➝ $3.00+37.61%
1/24/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral
1/6/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Foroohar
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform$11.00 ➝ $2.00-34.64%
1/6/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform$14.00 ➝ $7.00+128.76%
(Data available from 6/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












GRPH Price Target - Frequently Asked Questions

What is Graphite Bio's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Graphite Bio stock is Hold based on the current 1 sell rating and 8 hold ratings for GRPH. The average twelve-month price prediction for Graphite Bio is $3.33 with a high price target of $7.00 and a low price target of $2.00. Learn more on GRPH's analyst rating history.

Do Wall Street analysts like Graphite Bio more than its competitors?

Analysts like Graphite Bio less than other Medical companies. The consensus rating for Graphite Bio is Hold while the average consensus rating for medical companies is Buy. Learn more on how GRPH compares to other companies.

Does Graphite Bio's stock price have much upside?

According to analysts, Graphite Bio's stock has a predicted upside of 31.67% based on their 12-month price targets.

What analysts cover Graphite Bio?

Graphite Bio has been rated by Royal Bank of Canada in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:GRPH) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -